The license includes compounds that were discovered by Scripps Research in collaboration with Poniard. The research collaboration was initiated in 2005 at Scripps Florida, a division of the Institute located in Palm Beach County, and later broadened to include The Scripps Research Institute, La Jolla, California.
Jerry McMahon, chairman and CEO of Poniard, said: “We are on target with our program at Poniard to identify a kinase drug candidate that has the potential to be combined with our lead product picoplatin, which is currently in a Phase III registration study for small cell lung cancer.”